CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.15 USD
0.00 (0.00%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $1.15 0.00 (0.00%) 6:56 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.15 USD
0.00 (0.00%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $1.15 0.00 (0.00%) 6:56 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Zacks News
Why CytomX Therapeutics (CTMX) Stock Might be a Great Pick
by Zacks Equity Research
CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Here's Why CytomX Therapeutics (CTMX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does CytomX Therapeutics (CTMX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for April 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 17th
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will CytomX Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor CytomX Therapeutics
Top Ranked Momentum Stocks to Buy for April 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 3rd
CytomX & Astellas Collaborate to Develop Novel Cancer Therapy
by Zacks Equity Research
CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -43.64% and -47.24%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will CytomX Therapeutics (CTMX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.36% and -40.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: CytomX Therapeutics (CTMX) Q2 Earnings Expected to Decline
by Zacks Equity Research
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 41.51% and 116.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in CytomX Therapeutics.
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -26.19% and -23.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: CytomX Therapeutics (CTMX) Q3 Earnings Expected to Decline
by Zacks Equity Research
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.94% and 29.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Amgen Enters Into an Immuno-Oncology Partnership With CytomX
by Zacks Equity Research
Amgen (AMGN) has entered into a strategic immuno-oncology collaboration with CytomX to jointly develop a T-cell engaging bispecific probody.
Should CytomX Therapeutics (CTMX) Be On Your Radar Now?
by Zacks Equity Research
CytomX Therapeutics (CTMX) seems to be overlooked by shareholders as its favorable estimate revisions are not well reflected by its share price performance.
Bristol-Myers Squibb and CytomX Therapeutics Extend Deal
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.